Marshall Wace North America’s TherapeuticsMD TXMD Stock Holding History

Marshall Wace North America’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,106	Closed	-$601K	–	1730
2021 Q2	$601K	Sell	10,106 -1,979	-16%	-$120K	﹤0.01%	1127
2021 Q1	$810K	Sell	12,085 -6,023	-33%	-$471K	﹤0.01%	1094
2020 Q4	$1.1M	Sell	18,108 -8,904	-33%	-$608K	﹤0.01%	924
2020 Q3	$2.13M	Buy	27,012 +12,445	+85%	+$992K	0.01%	566
2020 Q2	$910K	Buy	+14,567	New	+$848K	0.01%	784
2020 Q1	–	Sell	-21,614	Closed	-$2.62M	–	1609
2019 Q4	$2.62M	Buy	+21,614	New	+$3.11M	0.01%	523
2019 Q1	–	Sell	-276	Closed	-$53K	–	1910
2018 Q4	$53K	Buy	+276	New	+$67.3K	﹤0.01%	1240

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace North America's TXMD Position: Q3 2021 in Review

Marshall Wace North America sold out of TherapeuticsMD (TXMD) in Q3 2021, closing a stake of 10,106 shares — an estimated $601K sold.

Marshall Wace North America first reported a position in TXMD in Q4 2018 and held it in 7 quarters. The position peaked at $2.62M in Q4 2019. 149 funds tracked by Wall St. Rank hold TXMD as of Q3 2021.

Marshall Wace North America reported no remaining TherapeuticsMD position as of Q3 2021 after selling out during the quarter.
Marshall Wace North America sold 10,106 TherapeuticsMD shares in Q3 2021, an estimated $601K.
Marshall Wace North America first reported a position in TherapeuticsMD in Q4 2018 and held it in 7 quarters.
Marshall Wace North America's TherapeuticsMD position peaked at $2.62M in Q4 2019.
149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.